SCOTUS allows early notice from biosimilar applicants

12-06-2017

SCOTUS allows early notice from biosimilar applicants

sprng23 / iStockphoto.com

The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration (FDA) for their biosimilars.  


SCOTUS, Amgen, Sandoz, Neupogen, biologics, biosimilar, FDA, BPCIA, US Supreme Court

LSIPR